Pulmonary Vein Isolation: Comparing different energy sources - independent or complementary use?

Pulsed-field ablation (PFA) has rapidly emerged as a non-thermal modality for pulmonary vein isolation (PVI) in the treatment of atrial fibrillation. By delivering high-voltage, microsecond-scale electrical pulses, PFA produces irreversible electroporation of cardiomyocytes while preserving the extracellular matrix of adjacent structures. Compared with conventional thermal modalities, namely radiofrequency (RF) and cryoablation, PFA offers shorter procedural times, comparable or superior efficacy for paroxysmal atrial fibrillation, and a markedly reduced risk of esophageal injury, persistent phrenic nerve palsy, and pulmonary vein stenosis, as demonstrated in numerous randomized controlled trials and large registries. However, PFA introduces unique limitations: hemolysis with potential renal injury, acute and delayed coronary vasospasm when ablating near the coronaries, the need for deep sedation or general anesthesia in most current systems, and uncertain durability of non-pulmonary vein lesions including the mitral and cavotricuspid isthmuses. Thermal ablation retains advantages for lesions beyond the pulmonary veins matter most particularly along the cavotricuspid and mitral isthmuses. Dual-energy catheters that combine RF and PFA, and sequential colocalized RF + PFA strategies, are now in clinical evaluation and may allow operators to create stacked lesions which may offer benefits for lesion durability. PFA is poised to become the dominant energy source for PVI, but in current clinical practice it is best viewed as complementary to, rather than fully replacing, thermal ablation.